Abstract: Objective  To observe the short-term potassium-lowering effect and adverse reactions of sodium zirconium cyclosilicate dispersion in patients with hyperkalemia.  Methods  The clinical data of 50 inpatients with hyperkalemia who received sodium zirconium cyclosilicate dispersion at Xining City First People's Hospital from November 2020 to March 2022 were collected and retrospectively analyzed for the potassium-lowering effects after 2 hours and 8 hours post-medication as well as any adverse drug reactions.  Results  Blood potassium levels after 2 hours and 8 hours post-medication were significantly lower than those before medication (t=10.034 and 14.654, P＜0.001), while there were no significant differences in blood sodium, calcium, magnesium, CO2CP, ALT, and AST levels before and after medication (P>0.05). Scatter plot analysis showed a linear positive correlation between the degree of decrease in blood potassium at 2 hours and 8 hours post-medication and the pre-medication blood potassium levels (r=0.298 and 0.579, P=0.038 and ＜0.001). There was no statistically significant difference in the degree of potassium reduction between the group with GFR ≤15ml/min and the group with＞15 ml/min at both 2 hours and 8 hours post-medication (t=-1.452 and 1.594, P=0.153 and 0.118). During treatment, two patients experienced mild nausea after taking the drug.   Conclusion  Sodium zirconium cylcosilicate dispersion can safely and effectively reduce blood potassium levels within 2-8 hours in patients with hyperkalemia without severe adverse reactions.

Key words: Sodium zirconium cyclosilicate, Hyperkalemia, Short-term